Advertisement
UK markets close in 4 hours 28 minutes

  • FTSE 100

    8,094.24
    +53.86 (+0.67%)
     

  • FTSE 250

    19,695.75
    -23.62 (-0.12%)
     

  • AIM

    754.91
    +0.22 (+0.03%)
     

  • GBP/EUR

    1.1662
    +0.0017 (+0.15%)
     

  • GBP/USD

    1.2507
    +0.0045 (+0.36%)
     

  • Bitcoin GBP

    50,725.91
    -2,381.60 (-4.48%)
     

  • CMC Crypto 200

    1,350.45
    -32.12 (-2.32%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.92
    +0.11 (+0.13%)
     

  • GOLD FUTURES

    2,339.70
    +1.30 (+0.06%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,975.01
    -113.69 (-0.63%)
     

  • CAC 40

    8,028.27
    -63.59 (-0.79%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Baxalta in talks to buy U.S. hematology-oncology specialist - Bloomberg

Reuters - UK Focus

Aug 28 (Reuters) - Drugmaker Baxalta Inc is working with bankers to buy a U.S (Other OTC: UBGXF - news) .-based hematology and oncology specialist valued at about $2 billion, Bloomberg reported, citing people familiar with the matter.

The target could not immediately be identified, Bloomberg reported on Friday. (http://bloom.bg/1hljzzC)

Baxalta (Berlin: 9BX.BE - news) is also being pursued by drugmaker Shire Plc (Xetra: S7E.DE - news) , which has made a $30 billion bid for the company.

Baxalta, spun off from Baxter International Inc (NYSE: BAX - news) in July, was not immediately available for comment.

The discussions continue and there is no certainty that a deal will be reached, Bloomberg reported. (Reporting by Rosmi Shaji in Bengaluru; Editing by Kirti Pandey)